Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

French (CAC) Healthcare Sector Analysis

UpdatedJan 12, 2026
DataAggregated Company Financials
Companies55
  • 7D3.6%
  • 3M3.2%
  • 1Y8.0%
  • YTD3.4%

Over the last 7 days, the Healthcare industry has risen 3.6%, driven by gains from EssilorLuxottica Société anonyme of 5.5%. This means that the industry has gained 8.0% over the past year. As for the next few years, earnings are expected to grow by 15% per annum.

Sector Valuation and Performance

Has the French Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 13 Jan 2026€309.8b€114.8b€9.2b21.5x33.6x2.7x
Thu, 11 Dec 2025€298.7b€114.8b€9.5b19.5x31.5x2.6x
Sat, 08 Nov 2025€310.5b€114.8b€9.5b21.5x32.7x2.7x
Mon, 06 Oct 2025€304.1b€114.7b€9.4b21x32.3x2.7x
Wed, 03 Sep 2025€285.7b€114.4b€9.4b19.2x30.5x2.5x
Fri, 01 Aug 2025€282.8b€113.5b€9.0b22x31.3x2.5x
Sun, 29 Jun 2025€275.0b€112.6b€9.0b23.9x30.6x2.4x
Tue, 27 May 2025€294.1b€112.6b€8.8b23.4x33.4x2.6x
Thu, 24 Apr 2025€295.0b€111.7b€8.2b21.1x35.8x2.6x
Sat, 22 Mar 2025€319.7b€111.3b€10.2b24.1x31.4x2.9x
Mon, 17 Feb 2025€329.5b€110.8b€9.9b23.7x33.4x3x
Wed, 15 Jan 2025€285.0b€113.9b€9.1b21.1x31.4x2.5x
Fri, 13 Dec 2024€279.7b€113.9b€9.1b21.6x30.9x2.5x
Sun, 10 Nov 2024€284.1b€114.0b€9.1b22.2x31.3x2.5x
Tue, 08 Oct 2024€286.3b€112.6b€8.8b22.7x32.5x2.5x
Thu, 05 Sep 2024€291.5b€111.9b€8.6b22x34x2.6x
Sat, 03 Aug 2024€276.8b€111.6b€8.7b23.1x32x2.5x
Mon, 01 Jul 2024€261.5b€110.0b€9.0b21.2x28.9x2.4x
Wed, 29 May 2024€269.3b€110.0b€9.0b24.2x29.9x2.4x
Fri, 26 Apr 2024€269.8b€105.0b€7.6b22.8x35.4x2.6x
Sun, 24 Mar 2024€276.1b€104.7b€8.6b21x32.1x2.6x
Tue, 20 Feb 2024€263.5b€104.6b€9.0b20.1x29.1x2.5x
Thu, 18 Jan 2024€263.1b€104.0b€12.7b21.2x20.7x2.5x
Sat, 16 Dec 2023€259.1b€104.0b€12.7b20.5x20.4x2.5x
Mon, 13 Nov 2023€244.8b€104.3b€12.8b20x19.1x2.3x
Wed, 11 Oct 2023€269.6b€104.8b€12.5b20.1x21.6x2.6x
Fri, 08 Sep 2023€275.0b€104.9b€12.4b22.3x22.3x2.6x
Sun, 06 Aug 2023€269.3b€104.5b€12.5b21.7x21.5x2.6x
Tue, 04 Jul 2023€266.2b€103.8b€12.4b19.3x21.5x2.6x
Thu, 01 Jun 2023€263.1b€108.3b€12.1b20.5x21.7x2.4x
Sat, 29 Apr 2023€274.7b€108.3b€12.1b21.2x22.8x2.5x
Mon, 27 Mar 2023€267.8b€107.8b€12.4b20x21.5x2.5x
Wed, 22 Feb 2023€270.0b€106.0b€10.9b18.1x24.8x2.5x
Fri, 20 Jan 2023€267.2b€104.9b€10.5b18.1x25.4x2.5x
Price to Earnings Ratio

25.4x


Total Market Cap: €267.2bTotal Earnings: €10.5bTotal Revenue: €104.9bTotal Market Cap vs Earnings and Revenue0%0%0%
French Healthcare Sector Price to Earnings3Y Average 28.2x202420252026
Current Industry PE
  • Investors are optimistic on the French Healthcare industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 33.6x which is higher than its 3-year average PE of 28.2x.
  • The industry is trading close to its 3-year average PS ratio of 2.6x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have declined 4.3% per year over the last three years.
  • Meanwhile revenues for these companies have grown 3.1% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the French Healthcare sector?

FR Market2.18%
Healthcare3.64%
Pharma4.29%
Medical Equipment4.26%
Healthtech2.88%
Healthcare Services2.35%
Life Sciences1.12%
Biotech-2.66%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry which is trading above its 3-year average PE ratio of 42.6x.
    • Analysts are expecting annual earnings growth of 14.4%, which is higher than its past year's earnings decline of 2.1% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 63% over the next 5 years.
  • This is better than its past earnings decline of 22% per year.
  • In contrast, the Pharma industry is expected to see its earnings grow by 9.5% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
EL EssilorLuxottica Société anonyme€276.004.8%
+€5.8b		18.3%PE53.5x
SAN Sanofi€82.411.5%
+€1.5b		-13.2%PE15.6x
IPN Ipsen€129.3010.5%
+€1.0b		8.4%PE23.7x
ERF Eurofins Scientific€71.706.8%
+€805.8m		46.3%PE33.3x
IVA Inventiva€4.4111.8%
+€88.8m		105.8%PS49.6x

Latest News

MEDCL
€26.42
MedinCell
7D
10.5%
1Y
62.1%
MAAT
€4.93
MaaT Pharma
7D
-8.7%
1Y
-38.7%
SAN
€82.41
Sanofi
7D
1.5%
1Y
-13.2%

SAN: Future Upside Will Depend On Pipeline Approvals And Margin Discipline

Analysts have trimmed their fair value estimate for Sanofi from about €104.87 to roughly €102.77, pointing to slightly softer assumptions for revenue growth, profit margins and future P/E as key drivers of the updated price target outlook. Analyst Commentary Recent fair value adjustments for Sanofi sit against a backdrop of active price target revisions across European equities, including large financials, where several research desks have been updating their expectations.
ERF
€71.70
Eurofins Scientific
7D
6.8%
1Y
46.3%

ERF: Mixed Price Views And New Testing Capacity Will Shape Future Performance

Analysts have nudged their price target higher to about €66 from about €64, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E that align with recent mixed Street target moves between €60 and €63.50. Analyst Commentary Recent Street updates on Eurofins Scientific offer a mixed picture, with one price target moving higher and another moving lower, but both clustered in the low €60s.
IVA
€4.41
Inventiva
7D
11.8%
1Y
105.8%

IVA: 2026 Phase 3 MASH Readout Expected To Unlock Upside Repricing

Analysts have raised their price target on Inventiva to $12 from $3, citing growing confidence in upcoming lanifibranor data, a broader biotech re-rating, and what they view as a de-risked, best-in-class pipeline with multiple catalysts ahead. Analyst Commentary Recent Street research around Inventiva clusters around a more constructive view of its lead asset lanifibranor and the company’s late stage pipeline, which analysts link directly to their higher valuation frameworks and upgraded views on the stock.
EL
€276.00
EssilorLuxottica Société anonyme
7D
4.8%
1Y
18.3%
VLA
€4.22
Valneva
7D
11.9%
1Y
95.5%

VLA: Chikungunya Commercial Uncertainty Will Undermine Long Term Earnings Potential

Analysts have adjusted their price targets for Valneva, with updated assumptions that include a discount rate of 6.76%, revenue growth of 9.16%, a profit margin of 26.93% and a forward P/E of 13.87x, reflecting a recalibration of expectations around the company’s risk profile and earnings outlook. What's in the News Valneva and Serum Institute of India agreed to discontinue their license deal for the single shot chikungunya vaccine, with Valneva regaining full rights to manage supply and commercialization in endemic high risk countries within the funding framework agreed with CEPI and the European Union (Client Announcements).
DIM
€215.00
Sartorius Stedim Biotech
7D
0.3%
1Y
5.5%

DIM: Raised 2025 Guidance And Updated Assumptions Will Shape Balanced Outlook

Analysts have nudged their price expectations for Sartorius Stedim Biotech higher, with one recent move lifting a target to €250 from €230. This change reflects updated assumptions around discount rates, growth and P/E inputs.
CLARI
€3.79
Clariane
7D
-0.6%
1Y
104.3%

CLARI: Confirmed 2025 Guidance And Higher Future P/E Will Support Upside

Analysts have adjusted their price target on Clariane to reflect an unchanged fair value of €5.20, revised revenue growth and profit margin assumptions, and a higher future P/E of 16.77x. What's in the News Clariane SE confirmed its group earnings guidance for 2025, giving investors a clearer view of management expectations for the year (Key Developments).
BIM
€109.40
bioMérieux
7D
-2.5%
1Y
-0.5%

BIM: Expanding Veterinary Diagnostics Will Support Future Margin Strength And Upside Potential

Analysts have slightly trimmed their price target on bioMérieux, reflecting a modest recalibration of fair value to about €125.18 from €125.25. They cite recent target cuts and a more cautious outlook embedded in their updated growth and discount rate assumptions.
IPN
€129.30
Ipsen
7D
10.5%
1Y
8.4%

IPN: Guidance Upgrade And Competitive Pressures Will Shape A Cautious Yet Balanced Outlook

Analysts have reduced their price target on Ipsen from EUR 130.07 to EUR 105.00, citing increased competitive pressure on Somatuline as a key driver of the downgrade. Analyst Commentary Analysts note that the reduced price target reflects a reassessment of Ipsen's risk and reward profile in light of mounting competition for Somatuline, which is expected to weigh on both top line momentum and margin resilience.
ADOC
€6.18
Adocia
7D
-6.1%
1Y
6.0%
NANO
€17.24
Nanobiotix
7D
-4.9%
1Y
483.6%
GDS
€9.10
Ramsay Générale de Santé
7D
-2.6%
1Y
-28.1%

We Discuss Why Ramsay Générale de Santé SA's (EPA:GDS) CEO Compensation May Be Closely Reviewed

Dec 05
We Discuss Why Ramsay Générale de Santé SA's (EPA:GDS) CEO Compensation May Be Closely Reviewed
ALCLS
€3.63
Cellectis
7D
-7.5%
1Y
108.3%
ALCGM
€13.45
Cegedim
7D
-4.9%
1Y
-0.4%